ライフサイエンスコーパス: zoster

1 the causative agent of varicella and herpes zoster.

2 can reactivate later in life to cause herpes zoster.

3 ansiently increased after exposure to herpes zoster.

4 enteric ganglia and can reactivate to cause zoster.

5 ed by abdominal pain that might have enteric zoster.

6 varicella virus (SVV) reactivates to produce zoster.

7 acute cardiovascular events following herpes zoster.

8 n comparison with patients with acute herpes zoster.

9 saliva facilitates identification of enteric zoster.

10 D4 T-cell levels were found in patients with zoster.

11 differences between people with and without zoster.

12 reased stroke rate within 6 months following zoster.

13 nic obstructive pulmonary disease and herpes zoster.

14 s, rising to a >3-fold rate 5-12 weeks after zoster.

15 l but significantly increased risk of herpes zoster.

16 ganglion, in the absence of clinical herpes zoster.

17 n between statin use and incidence of herpes zoster.

18 rams, which may reduce stroke risk following zoster.

19 development of treatments for painful herpes zoster.

20 to establish latency and reactivate, causing zoster.

21 hly contagious agent of varicella and herpes zoster.

22 onia, and an increase observed for varicella zoster.

23 fter recovery in 9 of 9 tested subjects with zoster, 2 of 2 with zoster sine herpete, and 5 of 5 with

24 nsient local skin reactions: 1 (4.8%) herpes zoster, 3 (14.3%) transaminase elevation, and 1 (4.8%) i

25 95% confidence interval 1.00-1.08) or herpes zoster (adjusted HR 1.03; 95% confidence interval 1.00-1

26 consistent evidence of an increased risk of zoster after partner death.

27 lla), and the virus can reactivate and cause zoster after primary infection.

28 analysis, we found a similar risk of herpes zoster among statin users in the subgroup of patients wi

29 ent to about 17 000 fewer episodes of herpes zoster and 3300 fewer episodes of postherpetic neuralgia

30 ne effectiveness of about 62% against herpes zoster and 70-88% against postherpetic neuralgia.

31 ity and magnitude of the association between zoster and acute cardiovascular events.

32 zoster virus vaccine in preventing varicella-zoster and herpes zoster is well documented, as are many

33 atent in ganglia, and reactivates to produce zoster and multiple other serious neurological disorders

34 ate vaccine coverage and incidence of herpes zoster and postherpetic neuralgia consultations.

35 vaccination programme on incidence of herpes zoster and postherpetic neuralgia in this population.

36 ns with patients aged 60-89 years for herpes zoster and postherpetic neuralgia occurring between Oct

37 ns administered and consultations for herpes zoster and postherpetic neuralgia, and aggregated these

38 nuated vaccine against chickenpox and herpes zoster and providing a new target for intervention of ne

39 stroke and myocardial infarction [MI]) after zoster and to assess whether zoster vaccination modifies

40 ) for oral candidiasis, tuberculosis, herpes zoster, and bacterial pneumonia.

41 her infections (such as syphillis, varicella-zoster, and parvovirus B19), cytomegalovirus, and herpes

42 To examine whether herpes zoster antigen (also called varicella-zoster virus antig

43 Herpes zoster antigen was detected in 3 of 25 temporal arteries

44 patients, false-positive staining for herpes zoster antigen was detected in the presence of calcifica

45 False-positive staining for herpes zoster antigen was detected on several temporal artery b

46 Among the GCA-negative group, herpes zoster antigen was not detected in any biopsy.

47 3 patients had positive staining for herpes zoster antigen.

48 wise healthy elderly individuals who develop zoster as a consequence of viral reactivation are at ris

49 VZV-specific CD4-T cells in patients with zoster bear typical features of anergy.

50 is an important human pathogen, with herpes zoster being a major health issue in the aging and immun

51 ncidences of cytomegalovirus disease, herpes zoster, BK virus, and nephropathy, which led to the disc

52 VZV reactivation in enteric neurons (enteric zoster), but an absence of rash makes diagnosis difficul

53 Stroke risk may be increased following zoster, but evidence is sparse and could be explained by

54 monly thought to increase the risk of herpes zoster by causing immunosuppression.

55 o be associated with persistent disseminated zoster caused by the vaccine virus.

56 and acute MI in defined periods after herpes zoster compared to other time periods, within individual

57 Stroke rate was increased following zoster compared with the baseline unexposed period, then

58 (PCR) analysis for Herpes simplex, varicella zoster, cytomegalovirus, Epstein-Barr virus and Toxoplas

59 .88) individuals during the first 4 wk after zoster diagnosis (interaction p-value = 0.28).

60 re beneficiaries aged >/= 65 y with a herpes zoster diagnosis and either an ischemic stroke (n = 42,9

61 We included patients with a zoster diagnosis from the primary care or hospital-based

62 ardiovascular events in the first week after zoster diagnosis: a 2.4-fold increased ischemic stroke r

63 lgia is the most important symptom of herpes zoster disease and it is very difficult to treat.

64 lgia is the most important symptom of herpes zoster disease, which is caused by Varicella zoster Neve

65 e three routine cohorts, incidence of herpes zoster fell by 35% (incidence rate ratio 0.65 [95% 0.60-

66 case series methods to look for increases in zoster following death or catastrophic health event occu

67 inal pain helps to identify putative enteric zoster for investigation and treatment.

68 ion in the peripheral nervous system (herpes zoster) have been published, while exceedingly few inves

69 Each year, herpes zoster (HZ) affects 1 million U.S. adults, many of whom

70 shown a decrease in the incidence of herpes zoster (HZ) among human immunodeficiency virus (HIV)-inf

71 of millions of seniors are at risk of herpes zoster (HZ) and its complications.

72 decreased from 61.1% to 37.3% for the herpes zoster (HZ) burden of illness (BOI), from 66.5% to 35.4%

73 la vaccination on the epidemiology of herpes zoster (HZ) critically depends on the mechanism of immun

74 gency department (ED) utilization for herpes zoster (HZ) has not been examined to date.

75 emporal increases in the incidence of herpes zoster (HZ) have been reported but studies have examined

76 The risk for herpes zoster (HZ) in patients with psoriasis treated with biol

77 The incidence and severity of herpes zoster (HZ) increases with age.

78 Protection against herpes zoster (HZ) induced by the live attenuated zoster vaccin

79 Herpes zoster (HZ) is common and often severe in patients under

80 etic neuralgia (PHN) risk by reducing herpes zoster (HZ) occurrence, it is less clear whether the vac

81 healthy population, the protection of herpes zoster (HZ) vaccine in end-stage renal disease (ESRD) pa

82 erstanding long-term effectiveness of herpes zoster (HZ) vaccine is critical for determining vaccine

83 Recombinant herpes zoster (HZ) vaccines may be an alternative to the live-a

84 individuals are at increased risk of herpes zoster (HZ), even in the antiretroviral therapy (ART) er

85 and reactivation of latent VZV causes herpes zoster (HZ).

86 nd in rare cases, reactivate to cause herpes zoster (HZ).

87 icacy (VE) to reduce the incidence of herpes zoster (HZ).

88 l agent of varicella (chickenpox) and herpes zoster (HZ, shingles).

89 al acyclovir reduces the incidence of herpes zoster in a randomized, double-blind, placebo-controlled

90 ricella-zoster virus vaccine prevents herpes zoster in adults older than 50 years.

91 ine significantly reduced the risk of herpes zoster in adults who were 50 years of age or older.

92 with placebo, in reducing the risk of herpes zoster in older adults.

93 serious infections, and four cases of herpes zoster in patients who received tofacitinib during the t

94 vir prophylaxis significantly reduced herpes zoster incidence among HIV-infected persons.

95 the four catch-up cohorts was 33% for herpes zoster (incidence rate ratio 0.67 [0.61-0.74]) and 38% f

96 Disproportionality in reporting herpes zoster infection was higher for patients receiving fingo

97 Herpes zoster infection was reported in 6% of patients in the r

98 nd the rates of overall infection and herpes zoster infection were higher with tofacitinib than with

99 .26-2.91]); the proportion of serious herpes zoster infections was not higher than the proportion for

100 e were four serious infections, three herpes zoster infections, one myocardial infarction, and one is

101 Herpes zoster is common and can have serious consequences.

102 Herpes zoster is common and vaccine preventable.

103 whether statins increase the risk of herpes zoster is unknown.

104 ne in preventing varicella-zoster and herpes zoster is well documented, as are many of the mutations

105 ye disease (due to herpes simplex and herpes zoster) is a significant cause of visual impairment, and

106 young adults, potentially leading to herpes zoster later in life on reactivation from latency.

107 zoster disease, which is caused by Varicella zoster Nevertheless, the pathophysiological mechanisms i

108 erson-years of follow-up, 26 cases of herpes zoster occurred among those assigned acyclovir, compared

109 -based epidemiology study to describe herpes zoster ophthalmicus (HZO) prevalence and risk factors fo

110 Herpes zoster ophthalmicus and scleritis/episcleritis ICD-9 cod

111 cord can reliably be used to identify herpes zoster ophthalmicus cases.

112 oteworthy because the patient had had herpes zoster ophthalmicus diagnosed 3 weeks before the onset o

113 ger effect was observed for individuals with zoster ophthalmicus, rising to a >3-fold rate 5-12 weeks

114 ve controls, 11 of 16 positive controls with zoster or varicella (P < .0001), 2 of 2 patients with zo

115 settings were analyzed, including ophthalmic zoster (OZ) and postherpetic neuralgia (PHN).

116 ypercholesterolemia, hypertension, varicella zoster, peripheral vascular disease, and autoimmune dise

117 In 4 monkeys, a zoster rash developed 7 to 12 weeks after immunosuppress

118 during predefined periods up to 12 mo after zoster relative to unexposed time periods were calculate

119 The causes for zoster remain largely unknown.

120 Analysis at 24 to 48 h after zoster revealed SVV antigen in the lung alveolar wall, i

121 Herpes zoster (shingles) causes significant morbidity in immune

122 varicella (P < .0001), 2 of 2 patients with zoster sine herpete (P < .01), 6 of 11 patients with une

123 f 9 tested subjects with zoster, 2 of 2 with zoster sine herpete, and 5 of 5 with abdominal pain.

124 ogenicity and safety of an adjuvanted herpes zoster subunit (HZ/su) vaccine when coadministered with

125 infected persons have higher rates of herpes zoster than HIV-uninfected individuals.

126 causes varicella upon primary infection and zoster upon reactivation from latency in sensory ganglio

127 tion between partner bereavement and risk of zoster using electronic healthcare data covering the ent

128 immune competent (79%), and did not receive zoster vaccination at any point during the follow-up (82

129 Zoster vaccination did not appear to modify the associat

130 pansions in response to attenuated varicella-zoster vaccination in four pairs of adult identical twin

131 We found no evidence for a role of zoster vaccination in these associations.

132 Zoster vaccination increased the median magnitude (2.3-f

133 ion [MI]) after zoster and to assess whether zoster vaccination modifies this association.

134 INTERPRETATION: The herpes zoster vaccination programme in England has had a popula

135 In 2013, a herpes zoster vaccination programme was introduced in England f

136 Findings have implications for zoster vaccination programs, which may reduce stroke ris

137 Although it is evident that zoster vaccination reduces postherpetic neuralgia (PHN)

138 ecific CD4(+) T-cell response increase after zoster vaccination.

139 es to each VZV protein at baseline and after zoster vaccination.

140 We identified individual data on herpes zoster vaccinations administered and consultations for h

141 Live attenuated herpes zoster vaccine (HZV) reduces that risk, although questio

142 Herpes zoster vaccine (ZV) was administered as a second dose to

143 icacy and Safety Trial of 1 dose of licensed zoster vaccine (ZV; Zostavax; Merck) in 50-59-year-olds

144 Immunogenicity and safety of inactivated zoster vaccine (ZVIN) were evaluated in adults with auto

145 tradermal administration of live, attenuated zoster vaccine are needed to provide convincing evidence

146 Two doses of live-attenuated varicella-zoster vaccine are recommended for human immunodeficienc

147 gpELISA antibody compared with subcutaneous zoster vaccine at comparable doses.

148 Eligible patients received live zoster vaccine at investigators' discretion.

149 Because SPS placebo recipients were offered zoster vaccine before the LTPS began, there were no unva

150 Zoster vaccine continues to protect against HZ if recipi

151 ermine whether intradermal administration of zoster vaccine could enhance vaccine immunogenicity comp

152 Shingles Prevention Study (SPS) demonstrated zoster vaccine efficacy through 4 years postvaccination.

153 Herpes zoster vaccine for persons aged 50 years does not seem t

154 The live attenuated zoster vaccine generates immune responses similar to HZ.

155 Each partial dose of zoster vaccine given intradermaly had a gpELISA GMFR com

156 received the approved full or a 1/3 dose of zoster vaccine given subcutaneously or one of four intra

157 Full dose zoster vaccine given subcutaneously resulted in a gpELIS

158 gpELISA GMFR comparable to that of full dose zoster vaccine given subcutaneously.

159 We compared the immune responses to zoster vaccine in young and older to adults to increase

160 Zoster vaccine is licensed for persons aged 50 years or

161 The exposure variable was receipt of zoster vaccine prior to initiation of chemotherapy.

162 Intradermal zoster vaccine showed a greater increase in varicella-zo

163 We conducted a study to determine whether zoster vaccine was effective in patients who subsequentl

164 d in the small subgroup of persons receiving zoster vaccine within 60 days before chemotherapy, but t

165 s zoster (HZ) induced by the live attenuated zoster vaccine Zostavax (ZVL) wanes within 3-7 years.

166 cine, 35 to receive the 1/3 dose intradermal zoster vaccine, 34 to receive the 1/10 dose intradermal

167 ed: 52 to receive the full dose subcutaneous zoster vaccine, 34 to receive the 1/3 dose subcutaneous

168 ine, 34 to receive the 1/3 dose subcutaneous zoster vaccine, 34 to receive the full dose intradermal

169 ine, 34 to receive the full dose intradermal zoster vaccine, 35 to receive the 1/3 dose intradermal z

170 ine, 34 to receive the 1/10 dose intradermal zoster vaccine, and 34 to receive the 1/27 dose intrader

171 and 34 to receive the 1/27 dose intradermal zoster vaccine.

172 mmunization of a 78-year-old woman with live zoster vaccine.

173 n against HZ if they had previously received zoster vaccine.

174 as prior herpes simplex keratitis, varicella-zoster viral keratitis, the linear form of Thygeson's su

175 llowed by tuberculosis (n = 8) and varicella zoster virus (n = 7).

176 ned as a monopartite NLS, while in varicella-zoster virus (VZV) activity required an adjacent basic s

177 Intraocular varicella-zoster virus (VZV) and HSV type 1 (HSV-1) infections cau

178 Varicella zoster virus (VZV) antibody titers (measured by a VZV gl

179 Varicella zoster virus (VZV) antigen was found in all of 4 GCA-pos

180 ion of human neurons in vitro with varicella-zoster virus (VZV) at a low multiplicity of infection do

181 types 1 (HSV-1) and 2 (HSV-2), and varicella zoster virus (VZV) by weekly polymerase chain reaction i

182 Varicella-zoster virus (VZV) causes chickenpox and reactivation of

183 ectious, human-restricted pathogen varicella-zoster virus (VZV) causes chickenpox and shingles.

184 from clinical specimens.IMPORTANCE Varicella-zoster virus (VZV) causes chickenpox and shingles.

185 Varicella-zoster virus (VZV) causes chickenpox upon primary infect

186 Varicella-zoster virus (VZV) characteristically forms multinucleat

187 The neurotropic herpesvirus varicella-zoster virus (VZV) establishes a lifelong latent infecti

188 Varicella zoster virus (VZV) establishes latency in dorsal root, c

189 Varicella-zoster virus (VZV) establishes latency in human sensory

190 Varicella zoster virus (VZV) establishes lifelong persistence and

191 ilar magnitude memory responses to varicella-zoster virus (VZV) ex vivo restimulation measured by res

192 t for antiviral therapy.IMPORTANCE Varicella-zoster virus (VZV) has infected over 90% of people world

193 echanisms of neuronal infection by varicella-zoster virus (VZV) have been challenging to study due to

194 for herpes simplex virus (HSV) or varicella zoster virus (VZV) in 79% to 100% of cases of suspected

195 eports observe the reactivation of varicella zoster virus (VZV) in people who have recovered from ars

196 Reactivation of the varicella zoster virus (VZV) increases during aging.

197 Varicella-zoster virus (VZV) induces apoptosis in human fibroblast

198 Varicella-zoster virus (VZV) infection causes varicella, after whi

199 Transcriptional changes following varicella-zoster virus (VZV) infection of cultured human neurons d

200 y studied the role of autophagy in varicella-zoster virus (VZV) infection, and have observed that ves

201 Varicella-zoster virus (VZV) infections increasingly are reported

202 Varicella-zoster virus (VZV) is a common pathogen that causes chic

203 Varicella-zoster virus (VZV) is a highly contagious agent of varic

204 Varicella-zoster virus (VZV) is a highly neurotropic virus that ca

205 Varicella-zoster virus (VZV) is a human neurotropic alphaherpesvir

206 mediate early 62 protein (IE62) of varicella-zoster virus (VZV) is a major viral trans-activator and

207 Varicella-zoster virus (VZV) is a ubiquitous pathogen that causes

208 Varicella-zoster virus (VZV) is an alphaherpesvirus that causes va

209 Varicella-zoster virus (VZV) is an extremely cell-associated herpe

210 Varicella-zoster virus (VZV) is highly cell associated when grown

211 tion, latency, and reactivation by varicella-zoster virus (VZV) is incompletely understood.

212 Varicella Zoster Virus (VZV) is the causative agent of varicella a

213 implex virus 1 (HSV-1), HSV-2, and varicella-zoster virus (VZV) on 695 consecutive cutaneous and muco

214 The varicella-zoster virus (VZV) open reading frame 54 (ORF54) gene en

215 ium formation, a characteristic of varicella-zoster virus (VZV) pathology in skin and sensory ganglia

216 The neurological damage caused by varicella-zoster virus (VZV) reactivation is commonly manifested a

217 The varicella-zoster virus (VZV) terminase components (pORF25, pORF30,

218 implex virus 1 (HSV-1), HSV-2, and varicella-zoster virus (VZV) to the BD Max system by using BD Max

219 Studies of varicella-zoster virus (VZV) tropism for T cells support their rol

220 Varicella zoster virus (VZV) typically causes chickenpox upon prim

221 Although a varicella-zoster virus (VZV) vaccine has been used for many years,

222 immunized with the live-attenuated varicella-zoster virus (VZV) vaccine.

223 Varicella-zoster virus (VZV) vasculopathy produces stroke, giant c

224 matous aortitis, and intracerebral varicella zoster virus (VZV) vasculopathy.

225 Varicella-zoster virus (VZV), a double-stranded DNA alphaherpesvir

226 mediate early 62 protein (IE62) of varicella-zoster virus (VZV), a major viral trans-activator, initi

227 Primary infection with varicella-zoster virus (VZV), a neurotropic alphaherpesvirus, resu

228 egulation of gene transcription in varicella-zoster virus (VZV), a ubiquitous human neurotropic alpha

229 erpes simplex virus 1/2 (HSV-1/2), varicella-zoster virus (VZV), cytomegalovirus (CMV), or enteroviru

230 s study, quantitative PCR detected varicella-zoster virus (VZV), herpes simplex virus 1 (HSV-1), and

231 Varicella-zoster virus (VZV), of the family Alphaherpesvirinae, ca

232 od disease, chicken pox, caused by varicella zoster virus (VZV), over an 11-y period.

233 Like varicella-zoster virus (VZV), simian varicella virus (SVV) reactiv

234 icity of live-attenuated Oka/Merck varicella zoster virus (VZV)-containing vaccine (hereafter, "varic

235 In varicella-zoster virus (VZV)-infected primary human brain vascular

236 Boost of varicella zoster virus (VZV)-specific cellular immunity is a likel

237 To measure varicella-zoster virus (VZV)-specific immune responses using glyco

238 nd the sequence-divergent pathogen varicella zoster virus (VZV).

239 gainst hepatitis B virus (HBV) and varicella-zoster virus (VZV).

240 hat can occur with reactivation of varicella-zoster virus (VZV).

241 is associated with TA infection by varicella-zoster virus (VZV).

242 ge, which leads to reactivation of varicella zoster virus (VZV).

243 None have yet been reported in varicella-zoster virus (VZV; also known as human herpesvirus 3 [HH

244 athogen-specific stimulation (with varicella-zoster virus [VZV] and cytomegalovirus [CMV]).

245 sitive for herpes simplex virus or varicella zoster virus and evaluated between January 2002 and June

246 V to other herpes viruses, such as varicella zoster virus and possibly Epstein-Barr virus.

247 Varicella-zoster virus antigen was found in 45 of 70 GCA-negative

248 Varicella-zoster virus antigen was frequently found in perineurial

249 herpes zoster antigen (also called varicella-zoster virus antigen) was detectable in temporal artery

250 ting, through which reexposures to varicella-zoster virus are thought to reduce the individual risk o

251 ibodies against a major antigen of varicella-zoster virus called gE.

252 corresponding region from ORF61 of varicella-zoster virus did not rescue ND10 fusion.

253 nfirmed varicella (by detection of varicella zoster virus DNA or epidemiological link) from 42 days a

254 Leu297Val) and 1 in a patient with varicella-zoster virus encephalitis (p.Leu199Phe).

255 ypic spectrum of TLR3 mutations to varicella-zoster virus encephalitis and support the role of TLR3 g

256 ths 0, 1, 3) three doses of 50 mug varicella-zoster virus glycoprotein E (gE) adjuvanted with AS01B,

257 ceived 3 doses of HZ/su (50 microg varicella-zoster virus glycoprotein E [gE] combined with AS01B adj

258 ults, a subunit vaccine containing varicella-zoster virus glycoprotein E and the AS01B adjuvant syste

259 mized 1:1 to receive either HZ/su (varicella zoster virus glycoprotein E; AS01B Adjuvant System) and

260 ccine showed a greater increase in varicella-zoster virus gpELISA antibody compared with subcutaneous

261 re associated with protection from varicella zoster virus infection (hazard ratio, 0.43; 95% confiden

262 resided in a country with endemic varicella-zoster virus infection for 30 years or more were eligibl

263 t may favor reactivation of latent varicella-zoster virus infection.

264 ed susceptibility to bacterial and varicella zoster virus infections.

265 infection of host cells.IMPORTANCE Varicella-zoster virus is an important human pathogen, with herpes

266 One patient with varicella zoster virus meningitis and acute GVHD had iC9-T cells p

267 Available varicella-zoster virus models can be classified in 3 main families

268 d children and were independent of varicella-zoster virus or herpes-simplex virus 1 coinfection.

269 in accordance with clinical observations of zoster virus reactivation from high doses of arsenic.

270 ued success of the live attenuated varicella-zoster virus vaccine in preventing varicella-zoster and

271 The licensed live, attenuated varicella-zoster virus vaccine prevents herpes zoster in adults ol

272 , EBV, herpes-simplex virus 1, and varicella-zoster virus were studied in 1079 6-year-old children.

273 dentify nosocomial transmission of varicella-zoster virus with fatal outcome.

274 s, 3%; herpes simplex virus 1, 3%; varicella zoster virus, 3%; HHV7, 2%; and herpes simplex virus 2,

275 herpesvirus 6, human parechovirus, varicella-zoster virus, and Cryptococcus neoformans/Cryptococcus g

276 at childhood infections, including varicella zoster virus, are associated with an increased risk of a

277 infections (herpes simplex virus, varicella zoster virus, bacterial and fungal infections) did not s

278 owing to either herpes simplex or varicella zoster virus, by using the Standardization of Uveitis No

279 litis virus, herpes simplex virus, varicella zoster virus, cytomegalovirus, dengue virus and chikungu

280 other alphaherpesviruses, such as varicella-zoster virus, depend upon the capacity to navigate in ne

281 members of the herpesvirus family: varicella zoster virus, human cytomegalovirus, and Epstein-Barr vi

282 ovirus, dengue virus, Nipah virus, varicella-zoster virus, mumps virus, measles virus, lyssavirus, he

283 ponema pallidium, parvovirus, HIV, varicella zoster virus, Rubella, Cytomegalovirus, and Herpesviruse

284 associated (4460 [2465] pg/mL) and varicella-zoster virus-associated (5386 [1778] pg/mL) uveitis.

285 endent on the host cell, we tested varicella zoster virus-infected cell lysates and clinically isolat

286 e from baseline in IgG antibody to varicella-zoster virus-specific glycoproteins (gpELISA) measured a

287 galovirus, Epstein-Barr virus, and varicella zoster virus.

288 ated to herpes simplex viruses and varicella-zoster virus.

289 o activated by the closely related varicella zoster virus.

290 ns or recombination with wild-type Varicella zoster virus.

291 Overall vaccine efficacy against herpes zoster was 97.2% (95% confidence interval [CI], 93.7 to

292 Stroke incidence in periods following zoster was compared with incidence in other time periods

293 During a mean follow-up of 3.2 years, herpes zoster was confirmed in 6 participants in the vaccine gr

294 In the main analysis, the rate of herpes zoster was higher among users of statins relative to non

295 The case of herpes zoster was relatively mild and resolved without complica

296 association between partner bereavement and zoster were 1.05 (99% confidence interval, 1.03-1.07) in

297 mes of myocardial infarction (MI) and herpes zoster were also studied.

298 Serious or complicated cases of herpes zoster were uncommon.

299 and travels anterograde to the skin to cause zoster, which is often complicated by postherpetic neura

300 Reactivation from latency causes herpes zoster, which may be complicated by postherpetic neuralg

301 in source isolation, developed disseminated zoster with rash present for 1 day before being transfer